三氧化二砷治疗难治复发急性早幼粒细胞白血病的分子生物学疗效观察  

Study on Molecular Remission of Relapsed or Refractory Acute Promyelocytic Leukemia Trioxide Therapy

作　　者：李淑娈[1] 黎承萍[2] 李维佳[2] 丁纪元[1] 郑婉珍 

机构地区：[1]杭州第四医院(杭州市肿瘤医院)肿瘤治疗中心,杭州310002 [2]昆明医学院第一附属医院血液内科,昆明650031

出　　处：《中国医药导刊》2009年第4期663-664,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:观察三氧化二砷(AS_2O_3)治疗难治复发急性早幼粒细胞白血病(APL)的分子生物学疗效。方法:0.1%AS_2O_3注射液静脉滴注,连续28天为一疗程,并动态检测PML-RARa融合基因。结果:15例患者再次分子学完全缓解(CR)13例,CR率为86.7%,随访中2例再次出现PML-RARa融合基因阳性,给予AS_2O_3获得再次CR。结论:AS_2O_3诱导治疗难治复发APL患者分子生物学缓解率高,与化疗交替使用能进一步清除微小残留病。Objective：To evaluate the cytological and molecular remission of relapsed or refractory acute promyelocytic leukemia （APL） treated by AS2O3. Methods： 0. 1%AS2O3 was injected iv,dr ip,at a dose of 10mg daily for 28d,and PML-RARa fusion gene was performed regularly. Conclusions-Thirteen of 15 patients achieved complete remission （CR）, CR rate was 86. 7 %, PML-RARa fusion gene of two patients was positive again in the follow-up ,which achieved CR again after been given AS2O3. Conclusions：Tbe relapsed or refractory APL treated by AS2O3 can achieve high cytological and molecular remission rate, and minimal residual disease（MRD） can be removed furterly.

关 键 词：三氧化二砷 白血病 早幼粒细胞 PML—RARa融合基因 

分 类 号：R733.71[医药卫生—肿瘤]